Inovio Pharmaceuticals EBITDA 2006-2021 | INO

Inovio Pharmaceuticals ebitda from 2006 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Inovio Pharmaceuticals Annual EBITDA
(Millions of US $)
2020 $-119
2019 $-106
2018 $-89
2017 $-80
2016 $-73
2015 $-32
2014 $-38
2013 $-17
2012 $-21
2011 $-20
2010 $-17
2009 $-12
2008 $-13
2007 $-15
2006 $-12
2005 $-15
Inovio Pharmaceuticals Quarterly EBITDA
(Millions of US $)
2021-06-30 $-82
2021-03-31 $-52
2020-12-31 $-27
2020-09-30 $-35
2020-06-30 $-33
2020-03-31 $-24
2019-12-31 $-28
2019-09-30 $-23
2019-06-30 $-27
2019-03-31 $-27
2018-12-31 $-28
2018-09-30 $-25
2018-06-30 $-4
2018-03-31 $-31
2017-12-31 $-22
2017-09-30 $-28
2017-06-30 $-9
2017-03-31 $-21
2016-12-31 $-21
2016-09-30 $-19
2016-06-30 $-17
2016-03-31 $-15
2015-12-31 $-14
2015-09-30 $4
2015-06-30 $-15
2015-03-31 $-8
2014-12-31 $-11
2014-09-30 $-8
2014-06-30 $-10
2014-03-31 $-10
2013-12-31 $-7
2013-09-30 $1
2013-06-30 $-5
2013-03-31 $-6
2012-12-31 $-6
2012-09-30 $-6
2012-06-30 $-6
2012-03-31 $-4
2011-12-31 $-5
2011-09-30 $-6
2011-06-30 $-5
2011-03-31 $-4
2010-12-31 $-5
2010-09-30 $-4
2010-06-30 $-4
2010-03-31 $-4
2009-12-31 $-3
2009-09-30 $-3
2009-06-30 $-3
2009-03-31 $-3
2008-12-31 $-3
2008-09-30 $-3
2008-06-30 $-4
2008-03-31 $-3
2007-12-31 $-2
2007-09-30 $-5
2007-06-30 $-5
2007-03-31 $-4
2006-12-31 $-4
2006-09-30 $-3
2006-06-30 $-3
2006-03-31 $-3
2005-12-31 $-3
2005-09-30 $-3
2005-06-30 $-2
2005-03-31 $-7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.689B $0.007B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71